RECURRENT HEAD AND NECK CARCINOMA
Clinical trials for RECURRENT HEAD AND NECK CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEAD AND NECK CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT HEAD AND NECK CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: RECURRENT HEAD AND NECK CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo aims to boost immunotherapy for head and neck cancer
Disease control OngoingThis phase 2 trial tests whether adding ramucirumab to pembrolizumab (Keytruda) works better than pembrolizumab alone for people with PD-L1 positive head and neck cancer that has come back or spread. About 37 participants will receive either the combination or the single drug. Th…
Matched conditions: RECURRENT HEAD AND NECK CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New trial tests shorter radiation for head and neck cancer that has returned
Disease control TerminatedThis phase II trial compares two types of radiation for people whose head and neck cancer has come back and cannot be removed with surgery. One method delivers high-dose radiation in fewer sessions, while the other uses standard daily doses over several weeks. The study aims to s…
Matched conditions: RECURRENT HEAD AND NECK CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Matched conditions: RECURRENT HEAD AND NECK CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 06:00 UTC